Publisher
Springer Science and Business Media LLC
Reference54 articles.
1. Vonderheide, R. H. & June, C. H. Engineering T cells for cancer: our synthetic future. Immunological reviews 257, 7–13 (2014).
2. Bonini, C. & Mondino, A. Adoptive T‐cell therapy for cancer: The era of engineered T cells. European journal of immunology 45, 2457–2469 (2015).
3. Fesnak, A. D., June, C. H. & Levine, B. L. Engineered T cells: the promise and challenges of cancer immunotherapy. Nature Reviews Cancer 16, 566 (2016).
4. Sciences, G. Kite’s YescartaTM (Axicabtagene Ciloleucel) becomes first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy,
https://www.businesswire.com/news/home/20171018006639/en/
) (2018).
5. Heo, Y. J., Son, C. H., Chung, J.-S., Park, Y.-S. & Son, J. H. The cryopreservation of high concentrated PBMC for dendritic cell (DC)-based cancer immunotherapy. Cryobiology 58, 203–209 (2009).
Cited by
80 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献